Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
F 12.47 0.48% 0.06
DVAX closed up 0.32 percent on Wednesday, March 27, 2024, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.48%
NR7 Range Contraction 0.48%
Narrow Range Bar Range Contraction 0.48%
Gapped Up Strength 0.48%
Fell Below 20 DMA Bearish 0.81%
Gapped Up Strength 0.81%
Crossed Above 20 DMA Bullish -0.24%
MACD Bullish Signal Line Cross Bullish -0.24%
Up 3 Days in a Row Strength -0.24%
Up 4 Days in a Row Strength -0.24%

   Recent Intraday Alerts

Alert Time
Rose Above 20 DMA 19 minutes ago
60 Minute Opening Range Breakout 19 minutes ago
20 DMA Resistance 26 minutes ago
Possible NR7 about 22 hours ago
Fell Below Previous Day's Low 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dynavax Technologies Corporation Description

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Inflammatory Diseases Hepatitis B Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9

Is DVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.15
52 Week Low 9.485
Average Volume 1,922,353
200-Day Moving Average 13.62
50-Day Moving Average 12.82
20-Day Moving Average 12.44
10-Day Moving Average 12.16
Average True Range 0.33
RSI (14) 47.92
ADX 21.11
+DI 19.95
-DI 23.96
Chandelier Exit (Long, 3 ATRs) 12.29
Chandelier Exit (Short, 3 ATRs) 12.63
Upper Bollinger Bands 13.17
Lower Bollinger Band 11.71
Percent B (%b) 0.48
BandWidth 11.71
MACD Line -0.16
MACD Signal Line -0.19
MACD Histogram 0.0377
Fundamentals Value
Market Cap 1.6 Billion
Num Shares 129 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 30.27
Price-to-Sales 4.63
Price-to-Book 2.76
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.63
Resistance 3 (R3) 12.63 12.55 12.59
Resistance 2 (R2) 12.55 12.50 12.55 12.58
Resistance 1 (R1) 12.48 12.46 12.45 12.48 12.57
Pivot Point 12.41 12.41 12.39 12.41 12.41
Support 1 (S1) 12.34 12.35 12.30 12.34 12.25
Support 2 (S2) 12.26 12.32 12.26 12.24
Support 3 (S3) 12.19 12.26 12.23
Support 4 (S4) 12.19